Pacer Advisors Inc. Sells 299,354 Shares of IQVIA Holdings Inc. $IQV

Pacer Advisors Inc. lessened its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 29.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 728,498 shares of the medical research company’s stock after selling 299,354 shares during the period. Pacer Advisors Inc.’s holdings in IQVIA were worth $138,371,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the company. Harbor Capital Advisors Inc. boosted its position in shares of IQVIA by 2.9% in the third quarter. Harbor Capital Advisors Inc. now owns 2,795 shares of the medical research company’s stock valued at $531,000 after acquiring an additional 78 shares during the period. World Investment Advisors grew its holdings in shares of IQVIA by 2.3% during the 3rd quarter. World Investment Advisors now owns 80,520 shares of the medical research company’s stock worth $15,294,000 after purchasing an additional 1,773 shares in the last quarter. Vontobel Holding Ltd. increased its position in shares of IQVIA by 909.1% in the third quarter. Vontobel Holding Ltd. now owns 550,430 shares of the medical research company’s stock worth $104,549,000 after purchasing an additional 495,884 shares during the period. OLD National Bancorp IN bought a new position in IQVIA in the 3rd quarter valued at about $291,000. Finally, Farther Finance Advisors LLC raised its position in shares of IQVIA by 172.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,083 shares of the medical research company’s stock valued at $206,000 after buying an additional 685 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Morgan Stanley upped their price objective on IQVIA from $250.00 to $265.00 and gave the stock an “overweight” rating in a research report on Monday, December 1st. TD Cowen downgraded shares of IQVIA from a “buy” rating to a “hold” rating and increased their price objective for the company from $206.00 to $215.00 in a research note on Monday, November 3rd. BMO Capital Markets began coverage on IQVIA in a research note on Thursday, November 13th. They issued an “outperform” rating and a $260.00 price target for the company. Evercore ISI boosted their price objective on IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 8th. Finally, UBS Group raised their price objective on shares of IQVIA from $225.00 to $250.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $243.19.

IQVIA Price Performance

Shares of NYSE IQV opened at $226.00 on Friday. The company has a market capitalization of $38.49 billion, a PE ratio of 31.00, a P/E/G ratio of 2.50 and a beta of 1.37. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $234.29. The firm has a fifty day simple moving average of $220.73 and a 200 day simple moving average of $194.34.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The business had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. During the same quarter in the prior year, the firm posted $2.84 earnings per share. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insider Activity at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the sale, the insider directly owned 27,108 shares in the company, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.60% of the stock is currently owned by company insiders.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.